Fluca

Quick links to important sections

Fluca

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluca

What is Fluca? Understanding the Ophthalmic Combination

Fluca is a pharmaceutical product, available by prescription, defined as a fixed combination ophthalmic suspension (eye drops) used for topical application to the eye. This combination uniquely integrates two different synthetic active ingredients to address both the immediate allergic reaction and the resulting inflammation.

Property Description
Active ingredient Fluorometholone, Sodium Cromoglycate
Form Sterile Ophthalmic Suspension (Eye Drops)
Pharmacological class Topical Glucocorticoid (Corticosteroid) & Mast Cell Stabilizer
Route of Administration Ophthalmic (Topical to the eye)
Origin Synthetic Chemical Compounds

The Combined Identity: Definition and Formulation Type

Fluca is precisely manufactured as a sterile ophthalmic suspension, representing a fixed combination product that targets the complexity of allergic eye conditions. Unlike single-agent steroid drops, the inclusion of two key pharmacological classes—the Glucocorticoids and the Mast Cell Stabilizers—is the defining synthetic feature of Fluca. This dual approach is clinically recognized for providing a more comprehensive strategy than sequential use of separate drops, which is particularly relevant in persistent allergic conditions.

Dual-Action Composition: Fluorometholone and Sodium Cromoglycate

Fluca's foundation is its two active components: Fluorometholone and Sodium Cromoglycate. Fluorometholone is a glucocorticoid known to reduce swelling and inflammation. Fluorometholone is used in treating corticosteroid-responsive inflammation of the anterior segment of the globe.

The complementary component, Sodium Cromoglycate, acts as a mast cell stabilizer. This agent prevents the release of inflammatory chemicals like histamine from mast cells. This component helps to proactively stop the body's overreaction that causes allergic symptoms.

General Purpose: Treating Allergic Inflammation

The general purpose of this fixed combination is to provide a comprehensive, two-pronged approach to manage the symptoms of eye conditions involving both allergic sensitivity and inflammatory reaction. By simultaneously reducing existing redness and swelling while minimizing the onset of allergic symptoms, the medicine is engineered to relieve discomfort and control the allergic inflammatory cycle. The sodium cromoglycate-fluorometholone combination is used for treating allergic conjunctivitis and improving symptoms like ocular itching.

What side effects are possible with Fluca?

Possible side effects and safety information

The safety profile of Fluca is primarily structured by the regulatory classifications related to its dual active ingredients, with serious risks most commonly documented in association with the corticosteroid component, Fluorometholone.

Officially Classified Adverse Reactions

Adverse effects are categorized by frequency and the body system affected, based on official regulatory documents. Common reactions, often localized to the eye, are transient and frequently noted upon immediate application.

Frequency Classification Documented Ocular Adverse Reactions
Common Elevated Intraocular Pressure (IOP), Ocular irritation, transient burning or stinging upon instillation.
Uncommon / Rare Posterior Subcapsular Cataract formation, damage to the optic nerve secondary to IOP elevation.
Not Known Blurred vision, eyelid swelling (edema), increased tearing (lacrimation), and taste perversion (dysgeusia).

Serious Ocular Safety Risks

Government regulatory labels document the potential for rare but serious outcomes, particularly with prolonged use. These include the risk of developing Glaucoma, resulting from sustained IOP elevation, and the formation of Posterior Subcapsular Cataract.

Contextual Safety Considerations

The product label outlines specific high-level safety constraints:

  • Infection Risk: The medicine is restricted in cases of active viral diseases (including ocular herpes simplex), fungal, mycobacterial, and untreated bacterial infections, as the corticosteroid component may mask or enhance infection.
  • Pediatric Use: Official documents note that children may have an increased risk of IOP elevation, which may occur earlier than in adults.
  • Reproduction: The medication is not recommended for use during pregnancy or lactation, based on regulatory safety profiles.

Overdose and Emergency Response

The official regulatory documents state that acute overdosage from the topical ophthalmic administration of Fluca is not expected to cause acute systemic toxicity. This classification is based on the extremely low systemic absorption profile of the active ingredients when applied to the eye.

Documented Overdose Presentations

If an excess amount of the suspension is inadvertently administered to the eye, the main documented occurrence is ocular irritation or the liquid exceeding the capacity of the conjunctival sac. In such cases, official guidance mandates that the affected eye should be flushed with water or normal saline.

The potential for serious outcomes, such as systemic hypercorticoidism or adrenal suppression, is primarily linked to scenarios of accidental oral ingestion or protracted, heavy use. Regulatory documents specifically note that pediatric ingestion is a scenario that necessitates heightened concern due to the increased risk of systemic effects in young children.

Emergency Actions and Required Help

Urgent medical attention is explicitly required in the event of accidental oral ingestion of the eye drops. Regulators instruct individuals to seek immediate medical advice and contact a regional poison control centre for management. If confirmed systemic exposure occurs, treatment procedures are defined as symptomatic and supportive, reflecting that no specific antidote is known for the active components. Close clinical observation or hospital monitoring may be required following significant exposure to manage potential systemic effects.

Therapeutic Uses of Fluca

What Fluca Treats: Main Uses and Benefits

Fluca is used across therapeutic domains involving localized allergic sensitivity and subsequent inflammation of the eye, applied across domains where additional symptomatic support is needed. This dual-action approach is commonly used in conditions marked by heightened patient distress, particularly when symptoms create noticeable interference with daily stability. The fixed combination is considered relevant for the management of allergic conjunctivitis and the related inflammatory conditions.

Primary Use and Symptom Relief

The primary therapeutic domain for Fluca is relevant for managing allergic conjunctivitis, used in situations involving recurrent or episodic manifestations, including both seasonal and perennial forms. The medication is commonly used across conditions presenting with acute episodes characterized by symptoms that interfere with daily functioning.

Fluca is used for managing symptom clusters that may become intense or disruptive, such as significant ocular itching, intense conjunctival redness, eye swelling, excessive tearing, and general eye discomfort. This support assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations.

“The medication is applied when symptom clusters appear suddenly or fluctuate, requiring dual supportive management.”

Quick Fact: Support for Allergic Symptom Clusters

Eligibility and Restrictions for Use

Eligibility for Fluca: Official Regulatory Rules

Fluca's eligibility profile is based on the official contraindications and restrictions of its components, primarily the corticosteroid. Use is defined by specific ocular status and patient age.

Contraindicated Populations

Fluca is contraindicated and must not be used in patients with:

  • Acute Viral Diseases of the cornea and conjunctiva, including Epithelial Herpes Simplex Keratitis, Vaccinia, and Varicella.
  • Fungal or Mycobacterial Infections of ocular structures.
  • Acute Purulent Untreated Infections of the eye.
  • Known Hypersensitivity to any component of the preparation.

Age-Related and Conditional Eligibility

Population Group Eligibility Status Restriction/Condition
Adults Eligible Use under standard labeled conditions.
Children under 2 years Not Established Safety and effectiveness have not been established.
History of Herpes Simplex Use with Great Caution Requires frequent monitoring.
Glaucoma Patients Use with Caution Intraocular pressure must be checked frequently.
Pregnancy Category C Use only if potential benefit justifies risk to the fetus.
Lactation Caution Required Unknown if drug is excreted in human milk; decision to discontinue drug or nursing is necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fluca (fluconazole) has a documented potential to interact with a wide range of medicinal products, primarily by inhibiting the activity of specific liver enzymes, namely cytochrome P450 isoenzymes CYP2C19, and to a lesser extent, CYP3A4 and CYP2C9. This inhibition results in increased concentrations of medicines that are metabolized by these enzymes.

Clinically Significant and Contraindicated Combinations

The co-administration of Fluca is strictly contraindicated with certain medicines that are known to prolong the QT interval and are metabolized via CYP3A4. These include, but are not limited to, cisapride, astemizole, pimozide, quinidine, and erythromycin. The combination is avoided due to the risk of serious cardiac arrhythmias, such as Torsade de Pointes.

Co-administration with terfenadine is also contraindicated when Fluca is administered at multiple daily doses of 400 mg or higher.

Required Monitoring and Dosage Adjustment

Interactions requiring careful monitoring and potential dosage adjustments include those with:

  • Anticoagulants (e.g., warfarin), due to increased risk of bleeding.
  • Oral hypoglycemic agents (e.g., sulfonylureas), due to increased risk of hypoglycemia.
  • CYP2C9 and CYP3A4 substrates, such as some statins, benzodiazepines, and certain antiepileptics.

Food intake does not affect the oral absorption of Fluca.

Mechanism of Action

Inhibition of Lanosterol 14-Alpha-Demethylase

This mechanistic domain involves Fluca's primary molecular target: the lanosterol 14-alpha-demethylase enzyme. By engaging this enzyme, the drug interrupts the biosynthesis of ergosterol, a sterol component of fungal cell membranes. This is achieved through a structural interaction that suppresses the enzyme's catalytic activity.


Modification of Membrane Structure

The consequence of enzyme inhibition is the accumulation of aberrant 14-alpha-methyl sterols and the depletion of functional ergosterol within the fungal cell membrane. This molecular imbalance modifies the membrane's architecture, increasing its permeability and negatively impacting the transport and signaling processes essential for membrane-dependent cellular activity. This downstream cascade leads to significant alteration in cellular homeostasis and pathway kinetics within the organism.

Dosage and Administration Information

Fluca is administered exclusively via the topical ophthalmic route as a sterile fixed-combination suspension applied directly to the affected eye(s). To maintain the necessary uniformity of the active ingredients within the suspension, the product must be shaken well immediately before using the drops.

The standardized dosing regimen involves the instillation of one to two drops per dose, which is typically administered two to four times daily. For acute symptom control, the frequency of application may be temporarily increased during the initial 24 to 48 hours. The safety and effectiveness of this specific combination product have not been established in pediatric patients younger than two years of age.

Proper use is further structured by specific administration constraints. A procedural constraint is that soft contact lenses must be removed prior to drop instillation and may only be reinserted 15 minutes following the application. The duration of therapy is generally short-term. Crucially, the cessation of treatment in chronic conditions must not be abrupt; instead, withdrawal is conducted by gradually decreasing the application frequency.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Activity and Formulation

Research has examined the biological activity of the drug components. The primary studies also evaluated the drug's properties as a multi-component formulation administered orally. The investigation of its basic activity is focused on specific molecular targets within the body's inflammatory response.


Clinical Research Findings

Efficacy and Function

Several non-randomized studies and literature reviews investigated whether the drug was associated with changes in measured parameters of physical function in a cohort of patients with moderate joint issues. Standardized measures of mobility were used to document observations.

  • Joint Parameters: One study assessed the time point and total duration of observed differences in self-reported joint parameters. Research evaluated results related to pain scores in chronic conditions, reporting outcomes through patient-reported pain intensity scales.
  • Quality of Life: Studies have explored whether the drug was associated with observed differences in self-reported scores for pain intensity and quality of life metrics. Findings remain limited regarding the full spectrum of patient-reported outcomes across diverse populations.

Administration and Extended Use

One primary study included a component where the drug was administered alongside food, allowing researchers to observe potential differences in absorption kinetics. Information on use in patients with severe conditions was not provided in the primary documents reviewed.

  • Extended Administration: Research has evaluated the reporting of adverse events during periods of extended administration to monitor potential long-term safety signals.

Key Studies & References

  1. A Phase III, Multicenter, Double-Blind Study of [Fluca] for Improvement of Physical Function in Patients with Moderate Joint Issues
  2. National Institute for Health and Care Excellence (NICE) Clinical Guideline: Assessment and Management of Osteoarthritis

Frequently Asked Questions (FAQ)

Common questions about Fluca (FAQ)


Q: Are the common side effects of Fluca serious?

Regulatory documents distinguish between side effects by how frequently they are reported. Common reactions are often localized and transient, such as stinging, burning, or a temporary increase in pressure inside the eye. More serious risks like glaucoma or cataract formation are classified separately as uncommon or rare events, which are typically associated with use over a prolonged period.


Q: Can Fluca be used during breastfeeding (lactation)?

Official information notes that it is unknown if the medicine is excreted in human milk. The regulatory text indicates that a decision must be made to either stop nursing or stop using the drug, taking into account the medical importance of the medicine to the patient.


Q: What happens if a person is allergic to an inactive ingredient in Fluca?

Official regulatory documents state that Fluca is contraindicated, meaning it must not be used, if a patient has a known hypersensitivity or allergy to the active substances or any other component of the preparation. This restriction includes both active and inactive ingredients.


Q: Does Fluca affect the liver or kidneys?

Regulatory information describes the systemic component, fluconazole, as acting by inhibiting certain liver enzymes (CYP450) in its oral form. This mechanism is central to potential drug interactions. Since Fluca is a topical ophthalmic suspension, its systemic absorption is expected to be low, and the label does not generally describe direct long-term liver or kidney consequences from its topical use.


Q: Can Fluca be crushed or split?

Fluca is a sterile ophthalmic suspension, meaning it is a liquid eye drop, not a solid tablet. The official instructions require the bottle to be shaken well before use and the liquid to be instilled into the eye. The medicine is not in a form that can be crushed or split.


Q: Is it normal if the color of Fluca tablets looks different sometimes?

Fluca is defined as a liquid suspension (eye drops), not a tablet. The color and appearance of the liquid formulation itself are officially described in the regulatory product information to ensure consistency and proper use.


Q: Is Fluca considered a high-risk medication?

Regulatory warnings are issued when a medicine presents serious potential risks, such as glaucoma, cataract formation, and the ability to mask an infection, especially when the medicine is used for prolonged periods. This categorization of risks in the regulatory document indicates that professional monitoring and use under supervision are necessary.


Q: Is Fluca a type of antibiotic or something else?

Fluca is classified in official documents as a fixed-combination product containing a Glucocorticoid (a type of corticosteroid) and a Mast Cell Stabilizer. It is not categorized as an antibiotic.


Q: Does Fluca affect sleep patterns?

Changes to sleep patterns are not listed as a common side effect of the topical ophthalmic product in official documents. The list of reported side effects does include some that are categorized as 'Incidence Not Known,' meaning they have been reported but their frequency is unestablished.


Q: Are there any specific foods I should avoid while using Fluca?

Official regulatory labels for the ophthalmic suspension do not direct patients to avoid any specific foods or beverages. For the oral form of the medicine, official information states that food intake does not affect the drug's absorption.


Q: Is Fluca effective for all people who take it?

Regulatory approval is based on clinical trials that demonstrate the medicine's efficacy in the specific patient populations studied. These studies report observed response rates. Official information does not guarantee 100% effectiveness across all patients.


Q: Is it normal to feel a mild headache when starting Fluca?

Headache is listed as an adverse event of 'Incidence Not Known' in official-style resources for the corticosteroid component. This means the event has been reported, but its frequency of occurrence is not established as common.


Q: Can Fluca interact with certain vitamins or minerals?

The drug's official interaction section focuses on medicines that affect specific liver enzymes (CYP450) and may lead to increased concentrations of those medicines. Common vitamins and minerals are not typically listed as having clinically significant interactions that require monitoring or avoidance.


Q: Are there different brand names for the medicine Fluca?

The active ingredients in Fluca are available under multiple different brand names as listed in official drug databases and product information documents.


Q: Why is careful monitoring sometimes needed while using Fluca?

Careful monitoring is required because of the potential risk of increased intraocular pressure (IOP), which is pressure inside the eye. This elevation of IOP could lead to serious conditions such as glaucoma or cataract formation, especially with prolonged use.


Q: Can Fluca be used by people with a history of heart issues?

The contraindications and warnings specifically focus on certain drug interactions with the oral form that can cause serious cardiac arrhythmias. A general eligibility statement for all people with a history of heart issues, outside of these specific interactions, is not provided in official regulatory documents.


Q: Does Fluca affect mood or energy levels?

Changes to mood or energy levels are not listed as common adverse reactions in the topical ophthalmic label. However, the corticosteroid component has been associated with rare systemic effects which could involve the nervous or endocrine systems, as described in regulatory documents.


Q: Is the long-term benefit of Fluca proven?

Regulatory documents refer to studies that have evaluated the drug over specific time periods, including those that monitor adverse events during 'extended administration.' The proven duration of benefit is outlined in the efficacy conclusions that support the medicine's approved use.


Q: What patient groups were included in the main Fluca clinical trials?

The research evidence section references studies involving cohorts with moderate joint issues and studies where the drug was administered alongside food, which outlines some of the characteristics of the patient populations studied.


Q: What is the shelf life of Fluca?

Official storage requirements define an expiration date (shelf life) for the unopened product, provided it is stored correctly. The official rules require that the contents be discarded 1 month after the bottle is first opened.


Q: Does Fluca affect driving or operating machinery?

The product label contains a warning that the medicine may cause transient blurred vision or other visual disturbances immediately following instillation. The official warning indicates that caution may be necessary when performing activities that require clear vision.

How should Fluca be stored and disposed of?

How to Store and Dispose of Fluca? (Ophthalmic Suspension)

The storage and handling of this ophthalmic suspension are defined by specific regulatory requirements to maintain product stability and sterility.


Required Storage Conditions

Requirement Specific Condition
Temperature Range Store between 2°C and 25°C (36°F and 77°F).
Handling & Protection Protect from freezing; store the bottle upright.
Container Rule Keep the container tightly closed when not in use.
Child Safety Keep the medicine out of the sight and reach of children.

Stability and Disposal

Once the bottle is first opened, any unused portion of the suspension must be discarded after 1 month (four weeks).

To dispose of unused or expired medicine, official guidance instructs consulting a healthcare professional or pharmacist for proper pharmaceutical waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluca found in:

A-Z Index: